The drug is taken by orally and works by modulating cystic fibrosis transmembrane conductance regulator (CFTR) and the calcium-activated chloride channel (CaCC), two chloride ion channels from the luminal side of the gastrointestinal tract. This is a first-in-class antisecretory antidiarrheal mechanism of action and it does not affect gastrointestinal motility, unlike the traditional antimotility drugs. As a result of the channel regulation, fewer chloride ions are secreted into the gut, which decreases the associated secretion of sodium ions and accompanying water, thus improving stool consistency and reducing the frequency of watery stools and duration of the diarrhea. The mechanism is selective for the CFTR and CaCC, as other channels involved in intestinal fluid secretion, namely sodium and potassium channels, are not affected by<unk> , nor is cAMP or calcium signaling.<unk>  is minimally, if at all, absorbed from the gut into the bloodstream, and is mostly excreted in the stools.
Crofelemer
Clinatec
Lesinurad
Ecallantide
Syclix
Itruvone
Tezacaftor
Vagisil